Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362917 · ClinicalTrials.gov registry record
Identification of β Cell Dysfunction in Relatives of Individuals With Type 1 Diabetes Mellitus
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 70
- Enrollment target
NCT04362917: Completed study, sponsored by Indiana University.
NCT04362917 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04362917 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
Study Summary
Despite the valuable information derived from older studies evaluating type 1 diabetes, the diabetes research community has, in large part, overlooked potential contributions of baseline abnormalities in β cell function to T1D development. Newer studies focusing on higher risk individuals often exclude family members without evidence of positive islet autoantibodies. New technologies to assay alternative biomarkers of β cell stress and death remain incompletely explored in both Ab negative and Ab positive family members of T1D patients. Specifically, modern biomarkers of β cell dysfunction have not been rigorously tested in combination with metabolic testing to fully understand their association with insulin secretion. The investigator's working hypothesis is that individuals at genetic risk for T1D exhibit baseline β cell dysfunction, even before development of detectable islet autoimmunity (seropositivity for islet Abs).
Primary Outcome
Our primary outcome is to assess if there is a difference in first phase beta call function in those genetically at risk for developing type 1 diabetes (first degree relatives) but who are islet autoantibody negative versus healthy controls with no family history of type 1 diabetes. We will calculate the first phase beta cell function by multiplying the acute c-peptide response to glucose (ACPRg) (nmol/L) by the insulin sensitivity (M/I) (x10-5 mmol/kg/min per pmol/L)
Interventions
- OTHER There is no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2021-08-27 |
What the finished NCT04362917 record still lists
NCT04362917 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which There is no intervention is the first listed.
NCT04362917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04362917 about?
NCT04362917 is a clinical study titled "Identification of β Cell Dysfunction in Relatives of Individuals With Type 1 Diabetes Mellitus". Despite the valuable information derived from older studies evaluating type 1 diabetes, the diabetes research community has, in large part, overlooked potential contributions of baseline abnormalities in β cell function to T1D development. Newer studies focusing on higher risk individuals often excl...
What is the current status of trial NCT04362917?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2017-11-14. Estimated completion is 2021-08-27.
What interventions are being tested in trial NCT04362917?
The interventions under investigation include: There is no intervention (OTHER).
Who is sponsoring clinical trial NCT04362917?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI